Imugene says Azer-cel could be best-in-class Allogeneic CAR T
November 13, 2023 at 03:41 pm EST
Share
(via NewsDirect)
Imugene Ltd (ASX:IMU) CEO Leslie Chong speaks with Proactive soon after announcing the company has passed a major milestone for its Azer-cel therapy treatment with the dosing of the first patient for its Phase 1b Allogeneic CAR T Clinical Trial. It follows a Phase 1a trial that included 84 patients across leading US healthcare centres and offered strong safety and efficacy signals according to IMU. The second part of this Phase 1 trial involves the study of Azer-cel in an ongoing, multi-centre clinical trial in patients with non-Hodgkin’s lymphoma blood cancer, and serves as a precursor to Phase 2 registrational (subject to FDA approval) in 2024.
“It is a great credit to our team that the Phase 1b study has been initiated and the first patient dosed, in under three months since acquiring the technology,” Chong said.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases
Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the bodyâs immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.